Navigator Medicines unveiled its plans to develop novel medicines for complex, heterogeneous autoimmune diseases on 27 August, revealing that it has raised $100m in series A funding from RA Capital Management and Forbion. In tandem, the privately held biotech formally announced a licensing agreement with IMBiologics Corp.
Navigator Medicines Emerges With $100m, Autoimmune Candidate
Backed by Forbion and RA Capital, Navigator will focus on novel OX40-targeted therapies for autoimmune diseases, with a clinical candidate in-licensed from IMBiologics.
More from Strategy
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.